{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T15:29:14Z","timestamp":1795188554624,"version":"4.10.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T00:00:00Z","timestamp":1603929600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T00:00:00Z","timestamp":1603929600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Shanghai Chest Hospital Talent Training Program"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Pleural effusion (PE) can be divided into benign pleural effusion (BPE) and malignant pleural effusion (MPE). There is no consensus on the identification of lung cancer-associated MPE using the optimal cut-off levels from five common tumor biomarkers (CEA, CYFRA 21-1, CA125, SCC-Ag, and NSE). Therefore, we aimed to find indicators for the auxiliary diagnosis of lung cancer-associated MPE by analyzing and then validating the optimal threshold levels of these biomarkers in pleural fluid (PF) and serum, as well as the PF\/serum ratio.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and method<\/jats:title><jats:p>The study has two sets of patients, i.e. the training set and the test set. In the training set, 348 patients with PE, between January 1, 2016 and December 31, 2017, were divided into BPE and MPE based on the cytological diagnosis. Subsequently, the optimal cut-off levels of tumor biomarkers were analyzed. In the test set, the diagnostic compliance rate was verified with 271 patients with PE from January 1, 2018 to July 31, 2019 to evaluate the auxiliary diagnostic value of the aforementioned indicators.<\/jats:p><\/jats:sec><jats:sec><jats:title>Result<\/jats:title><jats:p>In the training set, PF CEA at the cut-off value of 5.23\u00a0ng\/ml was the most effective indicator for MPE compared with other tumor biomarkers (all<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). In the test set, PF CEA at the cut-off value of 5.23\u00a0ng\/ml showed the highest sensitivity, specificity and accuracy, positive and negative predictive value among other tumor biomarkers, which were 99.0%, 69.1%, 91.6%, 90.7%, and 95.9%, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>PF CEA at the cut-off level of 5.23\u00a0ng\/ml was the most effective indicator for identifying lung cancer-associated MPE among the five common tumor biomarkers.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12931-020-01557-z","type":"journal-article","created":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T14:03:51Z","timestamp":1603980231000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Auxiliary diagnostic value of tumor biomarkers in pleural fluid for lung cancer-associated malignant pleural effusion"],"prefix":"10.1186","volume":"21","author":[{"given":"Hai","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changhui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinchen","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,29]]},"reference":[{"key":"1557_CR1","doi-asserted-by":"publisher","first-page":"102924","DOI":"10.1016\/j.ebiom.2020.102924","volume":"58","author":"S Wang","year":"2020","unstructured":"Wang S, Tian S, Li Y, Zhan N, Guo Y, Liu Y, et al. Development and validation of a novel scoring system developed from a nomogram to identify malignant pleural effusion. EBioMedicine. 2020;58:102924 ([published online ahead of print, 2020 Jul 30]).","journal-title":"EBioMedicine."},{"key":"1557_CR2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.lungcan.2018.11.020","volume":"127","author":"JC Thompson","year":"2019","unstructured":"Thompson JC, Fan R, Black T, Yu GH, Savitch SL, Chien A, et al. Measurement and immunophenotyping of pleural fluid EpCAM-positive cells and clusters for the management of non-small cell lung cancer patients. Lung Cancer. 2019;127:25\u201333.","journal-title":"Lung Cancer"},{"issue":"2","key":"1557_CR3","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s10147-016-1073-y","volume":"22","author":"M Feng","year":"2017","unstructured":"Feng M, Zhu J, Liang L, Zeng N, Wu Y, Wan C, et al. Diagnostic value of tumor markers for lung adenocarcinoma-associated malignant pleural effusion: a validation study and meta-analysis. Int J Clin Oncol. 2017;22(2):283\u201390.","journal-title":"Int J Clin Oncol"},{"issue":"3","key":"1557_CR4","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.ccm.2013.05.004","volume":"34","author":"JM Thomas","year":"2013","unstructured":"Thomas JM, Musani AI. Malignant pleural effusions: a review. Clin Chest Med. 2013;34(3):459\u201371.","journal-title":"Clin Chest Med"},{"issue":"Suppl 2","key":"1557_CR5","doi-asserted-by":"publisher","first-page":"ii4","DOI":"10.1136\/thx.2010.136978","volume":"65","author":"C Hooper","year":"2010","unstructured":"Hooper C, Lee YC, Maskell N, BTS Pleural Guideline Group. Investigation of a unilateral pleural effusion in adults: British Thoracic Society Pleural Disease Guideline 2010. Thorax. 2010;65(Suppl 2):ii4-17.","journal-title":"Thorax"},{"issue":"9366","key":"1557_CR6","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1016\/S0140-6736(03)13079-6","volume":"361","author":"NA Maskell","year":"2003","unstructured":"Maskell NA, Gleeson FV, Davies RJ. Standard pleural biopsy versus CT-guided cutting-needle biopsy for diagnosis of malignant disease in pleural effusions: a randomised controlled trial. Lancet. 2003;361(9366):1326\u201330.","journal-title":"Lancet"},{"issue":"4","key":"1557_CR7","doi-asserted-by":"publisher","first-page":"271","DOI":"10.7326\/0003-4819-114-4-271","volume":"114","author":"R Menzies","year":"1991","unstructured":"Menzies R, Charbonneau M. Thoracoscopy for the diagnosis of pleural disease. Ann Intern Med. 1991;114(4):271\u20136.","journal-title":"Ann Intern Med"},{"issue":"4","key":"1557_CR8","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1097\/COC.0b013e3181aacbbf","volume":"33","author":"G Lombardi","year":"2010","unstructured":"Lombardi G, Zustovich F, Nicoletto MO, Donach M, Artioli G, Pastorelli D. Diagnosis and treatment of malignant pleural effusion: a systematic literature review and new approaches. Am J Clin Oncol. 2010;33(4):420\u20133.","journal-title":"Am J Clin Oncol"},{"issue":"6","key":"1557_CR9","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1055\/s-0030-1269835","volume":"31","author":"M Noppen","year":"2010","unstructured":"Noppen M. The utility of thoracoscopy in the diagnosis and management of pleural disease. Semin Respir Crit Care Med. 2010;31(6):751\u20139.","journal-title":"Semin Respir Crit Care Med"},{"issue":"8","key":"1557_CR10","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1002\/(SICI)1097-0142(19991015)86:8<1488::AID-CNCR15>3.0.CO;2-Y","volume":"86","author":"J Ferrer","year":"1999","unstructured":"Ferrer J, Villarino MA, Encabo G, Felip E, Bermejo B, Vil\u00e0 S, et al. Diagnostic utility of CYFRA 21-1, carcinoembryonic antigen, CA 125, neuron specific enolase, and squamous cell antigen level determinations in the serum and pleural fluid of patients with pleural effusions. Cancer. 1999;86(8):1488\u201395.","journal-title":"Cancer"},{"issue":"3","key":"1557_CR11","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/BF00175946","volume":"172","author":"J Mezger","year":"1994","unstructured":"Mezger J, Calavrezos A, Drings P, Gatzemeier U, Kaukel E, Konietzko N, et al. Value of serum and effusion fluid CEA levels for distinguishing between diffuse malignant mesothelioma and carcinomatous pleural metastases. Lung. 1994;172(3):183\u20134.","journal-title":"Lung"},{"issue":"3","key":"1557_CR12","doi-asserted-by":"publisher","first-page":"328","DOI":"10.3109\/00313028609059485","volume":"18","author":"D Whitaker","year":"1986","unstructured":"Whitaker D, Shilkin KB, Stuckey M, Nieuwhof WN. Pleural fluid CEA levels in the diagnosis of malignant mesothelioma. Pathology. 1986;18(3):328\u20139.","journal-title":"Pathology"},{"key":"1557_CR13","doi-asserted-by":"publisher","DOI":"10.1088\/1361-6560\/ab9e58","author":"Yu Gao","year":"2020","unstructured":"Gao Yu, Kalbasi A, Hsu W, Ruan D, Jie Fu, Shao J, et al. Treatment effect prediction for sarcoma patients treated with preoperative radiotherapy using radiomics features from longitudinal diffusion-weighted MRI. Phys Med Biol. 2020. https:\/\/doi.org\/10.1088\/1361-6560\/ab9e58 .","journal-title":"Phys Med Biol."},{"issue":"18","key":"1557_CR14","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1056\/NEJMc1803858","volume":"378","author":"G Perricone","year":"2018","unstructured":"Perricone G, Airoldi A, Vangeli M. Pleural disease. N Engl J Med. 2018;378(18):1753\u20134.","journal-title":"N Engl J Med"},{"issue":"5","key":"1557_CR15","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.arbres.2013.11.007","volume":"50","author":"JM Porcel","year":"2014","unstructured":"Porcel JM, Esquerda A, Vives M, Bielsa S. Etiology of pleural effusions: analysis of more than 3,000 consecutive thoracenteses. Arch Bronconeumol. 2014;50(5):161\u20135.","journal-title":"Arch Bronconeumol"},{"key":"1557_CR16","doi-asserted-by":"publisher","first-page":"175346661880866","DOI":"10.1177\/1753466618808660","volume":"12","author":"JM Porcel","year":"2018","unstructured":"Porcel JM. Biomarkers in the diagnosis of pleural diseases: a 2018 update. Ther Adv Respir Dis. 2018;12:1753466618808660.","journal-title":"Ther Adv Respir Dis"},{"issue":"16\u201317","key":"1557_CR17","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/j.clinbiochem.2016.08.006","volume":"49","author":"R Tozzoli","year":"2016","unstructured":"Tozzoli R, Basso SM, D\u2019Aurizio F, Metus P, Lumachi F. Evaluation of predictive value of pleural CEA in patients with pleural effusions and histological findings: a prospective study and literature review. Clin Biochem. 2016;49(16\u201317):1227\u201331.","journal-title":"Clin Biochem"},{"issue":"4","key":"1557_CR18","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1378\/chest.128.4.2298","volume":"128","author":"JH Lee","year":"2005","unstructured":"Lee JH, Chang JH. Diagnostic utility of serum and pleural fluid carcinoembryonic antigen, neuron-specific enolase, and cytokeratin 19 fragments in patients with effusions from primary lung cancer. Chest. 2005;128(4):2298\u2013303.","journal-title":"Chest"},{"issue":"13\u201314","key":"1557_CR19","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.clinbiochem.2010.05.016","volume":"43","author":"JS Hackbarth","year":"2010","unstructured":"Hackbarth JS, Murata K, Reilly WM, Algeciras-Schimnich A. Performance of CEA and CA19-9 in identifying pleural effusions caused by specific malignancies. Clin Biochem. 2010;43(13\u201314):1051\u20135.","journal-title":"Clin Biochem"},{"key":"1557_CR20","doi-asserted-by":"publisher","first-page":"175883591985034","DOI":"10.1177\/1758835919850341","volume":"11","author":"K Hackner","year":"2019","unstructured":"Hackner K, Errhalt P, Handzhiev S. Ratio of carcinoembryonic antigen in pleural fluid and serum for the diagnosis of malignant pleural effusion. Ther Adv Med Oncol. 2019;11:1758835919850341.","journal-title":"Ther Adv Med Oncol"},{"issue":"2","key":"1557_CR21","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.lungcan.2011.11.012","volume":"76","author":"M Grunnet","year":"2012","unstructured":"Grunnet M, Sorensen JB. Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer. 2012;76(2):138\u201343.","journal-title":"Lung Cancer"},{"issue":"3","key":"1557_CR22","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1177\/1724600819868234","volume":"34","author":"L Fu","year":"2019","unstructured":"Fu L, Wang R, Yin L, Shang X, Zhang R, Zhang P. CYFRA21-1 tests in the diagnosis of non-small cell lung cancer: a meta-analysis. Int J Biol Markers. 2019;34(3):251\u201361.","journal-title":"Int J Biol Markers"},{"issue":"1","key":"1557_CR23","doi-asserted-by":"publisher","first-page":"e80","DOI":"10.5301\/jbm.5000177","volume":"31","author":"L Wang","year":"2016","unstructured":"Wang L, Wang D, Zheng G, et al. Clinical evaluation and therapeutic monitoring value of serum tumor markers in lung cancer. Int J Biol Markers. 2016;31(1):e80\u20137.","journal-title":"Int J Biol Markers"},{"issue":"1","key":"1557_CR24","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.lungcan.2013.01.002","volume":"80","author":"K Okamura","year":"2013","unstructured":"Okamura K, Takayama K, Izumi M, Harada T, Furuyama K, Nakanishi Y. Diagnostic value of CEA and CYFRA 21\u20131 tumor markers in primary lung cancer. Lung Cancer. 2013;80(1):45\u20139.","journal-title":"Lung Cancer"},{"issue":"4","key":"1557_CR25","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1183\/09031936.93.02040366","volume":"2","author":"F Rodr\u00eeguez-Panadero","year":"1989","unstructured":"Rodr\u00eeguez-Panadero F, Borderas Naranjo F, L\u00f3pez MJ. Pleural metastatic tumours and effusions. Frequency and pathogenic mechanisms in a post-mortem series. Eur Respir J. 1989;2(4):366\u20139.","journal-title":"Eur Respir J."},{"issue":"5","key":"1557_CR26","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1136\/thx.21.5.437","volume":"21","author":"PC Meyer","year":"1966","unstructured":"Meyer PC. Metastatic carcinoma of the pleura. Thorax. 1966;21(5):437\u201343.","journal-title":"Thorax"},{"issue":"4","key":"1557_CR27","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1002\/cam4.2809","volume":"9","author":"Z Chen","year":"2020","unstructured":"Chen Z, Wang Y, Fang M. Analysis of tumor markers in pleural effusion and serum to verify the correlations between serum tumor markers and tumor size, TNM stage of lung adenocarcinoma. Cancer Med. 2020;9(4):1392\u20139.","journal-title":"Cancer Med"},{"issue":"140","key":"1557_CR28","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1183\/16000617.0019-2016","volume":"25","author":"I Psallidas","year":"2016","unstructured":"Psallidas I, Kalomenidis I, Porcel JM, Robinson BW, Stathopoulos GT. Malignant pleural effusion: from bench to bedside. Eur Respir Rev. 2016;25(140):189\u201398.","journal-title":"Eur Respir Rev"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-020-01557-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12931-020-01557-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-020-01557-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T14:14:41Z","timestamp":1669385681000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-020-01557-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,29]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1557"],"URL":"https:\/\/doi.org\/10.1186\/s12931-020-01557-z","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,29]]},"assertion":[{"value":"31 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study has been approved by the Ethics Committee and the Institutional Review Board and was conducted in accordance with the Helsinki Declaration.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All patients agreed that their information was used for research and signed written informed consent before the collection of information.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors state that they have no conflict of interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"284"}}